Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot

Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury. The post Sarepta’s Future in Gene Therapy…

Read More

Journalists Recap State of NIH Cancer Research and Abortion Law’s Effect on Clinical Decisions

KFF Health News chief Washington correspondent Julie Rovner discussed Trump administration cuts to the National Institutes of Health on WNYC’s “The Brian Lehrer Show” on June 3. Click here to hear Rovner on “The Brian Lehrer Show.” KFF Health News Southern correspondent Sam Whitehead discussed Georgia’s abortion laws on WUGA’s “The Georgia Health Report” on May…

Read More

Alzheimer’s Disease Now Has Its First FDA-Cleared Blood Test

Fujirebio Diagnostics’ blood test for Alzheimer’s disease offers a less expensive and less invasive alternative compared to medical imaging and tests of cerebrospinal fluid. But competition looms from blood-based tests in development by other diagnostics companies. The post Alzheimer’s Disease Now Has Its First FDA-Cleared Blood Test appeared first on MedCity News.

Read More